Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a combination of two antibiotics, clindamycin and tetracycline, used together primarily for their antibacterial effects. Clindamycin is a lincosamide antibiotic effective against susceptible anaerobic bacteria and gram-positive cocci; it works by inhibiting bacterial protein synthesis. Tetracycline is a broad-spectrum antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. The combination may be used in infections where both drugs' spectra are beneficial or in conditions like hidradenitis suppurativa, where antibiotic combinations are employed for their antibacterial and anti-inflammatory properties. Clindamycin also suppresses bacterial toxin production and leukocyte chemotaxis, reducing inflammation. Tetracycline requires administration considerations such as avoiding concurrent intake with iron-containing products to prevent absorption interference.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clindamycin + tetracycline.